|
|
Thrombolysis requires further testing in large randomized trials because the risks seem substantial,and the benefit uncertain.The time window for effective treatment remains unclear.There is no objective evidence to suggest that tPA is safer than streptokinase;the apparent hazards and benefits may be similar when differences in trial design and baseline variables are accounted for. |
|